overdetection

overdetection

(ō″vĕr-dĕ-tek′shŏn)
The identification of clinically insignificant disease during screening programs designed to detect severe or malignant illnesses.
References in periodicals archive ?
Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer.
There is some debate on whether this test should be performed in asymptomatic men because of associated overdetection or overtreatment of indolent disease.
We think that we've seen a leveling of overdetection, but I think we'll see another round of overdetection, because of a lowering PSA threshold to prompt biopsy; aggressive rescreening, the use of PSA velocity at low PSA values to prompt biopsy, and the use of saturation biopsies," he said during the conference, sponsored by the American Association for Cancer Research and the Prostate Cancer Foundation.
Thus 1 sequela of breast screening programs worldwide has been a marked increase in the overdetection and overtreatment of DCIS.
Lead times and overdetection due to PSA screening: estimates from the European randomized study of screening for prostate cancer.
Underdetection and overdetection are specific situations requiring constant supervision.
These results highlight the potential for problems in microbiology proficiency to contribute to either underdetection or overdetection of resistant organisms.
The influence of creatinine method bias on the estimated GFR (eGFR) was perhaps the paramount problem, together with concerns of overdetection among some clinicians as the scale of the CKD "epidemic" came to be appreciated.
Though screening could lead to a reduction of up to a third in mortality from prostate cancer, this would be at the risk of overdetection and overtreatment.
The concern of overdetection must be weighed against the risk of clinically significant malignancy being missed by inadequate biopsy strategies that have considerable false-negative rates.
Other problems, such as a reduced diagnostic sensitivity and the overdetection with a 4-[micro]g/L PSA cutoff and subsequent overtreatment (5), support the need for new biomarkers that overcome these obstacles.
The study offers evidence for the use of active surveillance, based on changes in disease risk over time, as a means of addressing the significant problem of overdetection and overtreatment of prostate cancer in patients with indolent disease, said Dr.